AVR — Anteris Technologies Global Corp.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 2011514 ·
Last close
$9.47
Market Cap
$921.83M
52W High
$10.14
52W Low
$4.99
ADV30
1,143,587
Next earnings
2026-05-14
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Sep 2025
Jun 2025
Mar 2025

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,100,678
Investing CF
$-553,064
Financing CF
$18,486,944
CapEx
$-553,064
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.09
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-257,012,631
Inventory
$459,603
Receivables
$2,095,604
ST Investments
EBIT TTM
$-21,782,712
Pretax Income TTM
$-21,794,452
Interest Exp TTM
$11,740
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,851,000
EBITDA
$-94,434,000
Free Cash Flow
$-52,655,876
Enterprise Value
$630,178,176
Total Cash
$282,699,008
Total Debt
$3,735,000
Shares Out
97,342,203
Trailing EPS
$-2.22
Book Value
$2.86
ROE
-59.2%
ROA
-34.0%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025
Dec 2024
Dec 2023 2,734,821 -46,656,491 -46,021,841 30,527,440 11,629,367 -34,631,516
Dec 2022 3,200,711 -31,487,645 -30,563,800 15,985,506 6,952,284 -29,416,702
Dec 2021 5,830,534 -16,320,961 -17,171,057 21,433,693 10,908,758 -14,438,162

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.98

Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $9.47 · call volume: 260 · put volume: 102
Expected Move to 2026-06-18: ±$1.44 (15.21%) — implied range $8.03$10.91 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
STVN Stevanato Group S.p.A. $899.75M $18.10
AORT ARTIVION, INC. $1.01B $20.88
DRTS Alpha Tau Medical Ltd. $830.09M $9.19
INMD InMode Ltd. $824.57M $13.56
CNMD CONMED Corp $1.11B $36.90

News headlines (Yahoo Finance, 1h cache)

France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
2026-06-08 23:22 · Yahoo
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
2026-06-08 10:00 · Yahoo
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation
2026-05-13 20:00 · Yahoo
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
2026-05-13 12:39 · Yahoo
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
2026-05-13 01:33 · Yahoo
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
2026-05-12 23:43 · Yahoo
Anteris Announces Results for the First Quarter of 2026
2026-05-12 23:00 · Yahoo
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances
2026-05-07 01:45 · Yahoo
Anteris treats first US patients in DurAVR pivotal trial
2026-05-07 01:45 · Yahoo
Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve
2026-05-06 17:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.